Charles River Labs stock rises as management signals growth inflection

Published on 09/15/2026 at 21:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Charles River Labs stock has gained over 20 percent in recent months as management highlighted an inflection toward better growth and margins at a September 2026 conference. The company now expects Manufacturing margins near 40 percent and at least USD 500 million in annual free cash flow in normal years.

Moderner CRO-Forschungscampus mit Glasfassade in Wilmington Massachusetts — Charles River Laboratories Forschungscampus in Wilmington Massachusetts, modernes Glaslaborgebäude, ISIN US1591881009, Außenansicht, Illustration mit AI erstellt.

Charles River Laboratories International, Inc. stock (ISIN US1591881009) has climbed more than 20 percent over the past year as management used a September 2026 investor conference to signal that the business is entering a new phase of stabilization and growth, with stronger margins and cash generation expected in the second half of 2026.

Conference signals inflection in 2026 performance

As Investing.com reported on September 14, 2026, Charles River Laboratories used the Morgan Stanley 24th Annual Global Healthcare Conference to emphasize that it is at an inflection point, expecting better financial performance starting in the second half of 2026.

According to Investing.com, the company highlighted Drug Safety Assessment, or DSA, as a key driver of the recovery, with the segment posting a book-to-bill ratio of 1.19 in the second quarter of 2026, its highest level in about four years and above the 1.0 threshold for three consecutive quarters.

Management said at the same conference that it expects DSA revenue to accelerate in the second half of 2026 after returning to modest growth in the second quarter of 2026, while Microbial Solutions delivered high single-digit organic growth over the same period and is expected to remain a solid contributor.

Margins, cash flow and leverage underpin the story

In its conference presentation, Charles River Laboratories noted that Manufacturing segment margins were in the upper 30 percent range in the second quarter of 2026 and are expected to approach 40 percent in the back half of 2026, giving investors a clearer path to margin expansion across the group, according to Investing.com.

The company also raised its free cash flow guidance on its latest second-quarter earnings call, and management reiterated at the conference that Charles River Laboratories should generate at least USD 500 million in annual free cash flow in normal years, supporting both acquisition spending and share repurchases, as reported by Investing.com.

Year to date in 2026, Charles River Laboratories has deployed about USD 800 million in capital, including roughly USD 500 million for acquisitions and USD 300 million for share buybacks, while keeping its net debt to EBITDA leverage ratio at about 2.5 times, according to Investing.com.

At the same time, guidance for the Research Models and Services, or RMS, business still calls for a low single-digit revenue decline in full-year 2026, underlining that not all segments are in growth mode yet and that investors need to watch how quickly RMS stabilizes relative to the stronger DSA and Manufacturing trajectories, as noted by Investing.com.

Stock performance and AI-based price target context

Beyond management commentary, recent performance data show that Charles River Labs stock has delivered a positive return over the past year. An AI-based comparison of Charles River Laboratories with another healthcare stock indicated that over the last year Charles River Labs stock gained about 21.55 percent, versus a 70.99 percent rise for the comparator, underscoring that the shares have participated in the sector recovery but have not been the strongest performer, according to Danelfin.

The same AI analysis cited a last observed Charles River Labs stock price of USD 273.15 and an AI price target of USD 276.92, implying a potential upside of 1.38 percent from that level, with a high forecast of USD 327.11 and a low forecast of USD 210.35, according to Danelfin.

The AI-based metrics also show that Charles River Labs stock has returned about 0.29 percent over the most recent quarter and about minus 1.46 percent year to date, meaning that while the 21.55 percent gain over the last year is solid, more recent performance has been relatively flat or slightly negative, according to Danelfin.

Closing price context for investors

Per performance data cited above, Charles River Labs stock recently traded around USD 273.15 on its primary US exchange, corresponding to a market capitalization of about USD 13.28 billion as of mid-September 2026, based on figures reported by Danelfin.